Datasheet BA3178 Anti-P2RX6 Antibody

Total Page：16

File Type：pdf, Size：1020Kb

Product datasheet Anti-P2RX6 Antibody Catalog Number: BA3178 BOSTER BIOLOGICAL TECHNOLOGY Special NO.1, International Enterprise Center, 2nd Guanshan Road, Wuhan, China Web: www.boster.com.cn Phone: +86 27 67845390 Fax: +86 27 67845390 Email: [email protected] Basic Information Product Name Anti-P2RX6 Antibody Gene Name P2RX6 Source Rabbit IgG Species Reactivity human Tested Application WB Contents 500ug/ml antibody with PBS ，0.02% NaN3 , 1mg BSA and 50% glycerol. Immunogen A synthetic peptide corresponding to a sequence at the C-terminus of human P2X6(387-406aa VWRELALASQARLAECLRRS). Purification Immunogen affinity purified. Observed MW 60KD Dilution Ratios Western blot: 1:500-2000 Storage 12 months from date of receipt，-20℃ as supplied.6 months 2 to 8℃ after reconstitution. Avoid repeated freezing and thawing Background Information Purinergic receptor P2X-Like 1, also known as P2X6, is a protein that in humans is encoded by the P2RX6 gene. The encoded protein is associated with VE-cadherin at the adherens junctions of human umbilical vein endothelial cells. This gene belongs to the family of P2X receptors. P2RXL1 gene was mapped to chromosome 22q11 by fluorescence in situ hybridization. This gene is a receptor for ATP that acts as a ligand-gated ion channel. It can mediate rapid and selective permeability to cations. Reference Anti-P2RX6 Antibody被引用在0文献中。暂无引用 FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC AND CLINICAL USE. 1 Product datasheet Anti-P2RX6 Antibody Catalog Number: BA3178 BOSTER BIOLOGICAL TECHNOLOGY Special NO.1, International Enterprise Center, 2nd Guanshan Road, Wuhan, China Web: www.boster.com.cn Phone: +86 27 67845390 Fax: +86 27 67845390 Email: [email protected] Selected Validation Data Lane 1: U87 Cell LysateLane 2: 22RV1 Cell LysateLane 3: JURKAT Cell LysateLane 4: HT1080 Cell Lysate FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC AND CLINICAL USE. 2 Powered by TCPDF (www.tcpdf.org).

Copy Link

Recommended publications

Cells Δγ Lineage Choice and Shapes Peripheral Purinergic P2X7
Purinergic P2X7 Receptor Drives T Cell Lineage Choice and Shapes Peripheral δγ Cells This information is current as Michela Frascoli, Jessica Marcandalli, Ursula Schenk and of October 2, 2021. Fabio Grassi J Immunol 2012; 189:174-180; Prepublished online 30 May 2012; doi: 10.4049/jimmunol.1101582 http://www.jimmunol.org/content/189/1/174 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2012/05/30/jimmunol.110158 Material 2.DC1 http://www.jimmunol.org/ References This article cites 31 articles, 15 of which you can access for free at: http://www.jimmunol.org/content/189/1/174.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on October 2, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Purinergic P2X7 Receptor Drives T Cell Lineage Choice and Shapes Peripheral gd Cells Michela Frascoli,* Jessica Marcandalli,* Ursula Schenk,*,1 and Fabio Grassi*,† TCR signal strength instructs ab versus gd lineage decision in immature T cells.
[Show full text]
Cellular and Molecular Signatures in the Disease Tissue of Early
Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
[Show full text]
Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
[Show full text]
Ion Channels
UC Davis UC Davis Previously Published Works Title THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels. Permalink https://escholarship.org/uc/item/1442g5hg Journal British journal of pharmacology, 176 Suppl 1(S1) ISSN 0007-1188 Authors Alexander, Stephen PH Mathie, Alistair Peters, John A et al. Publication Date 2019-12-01 DOI 10.1111/bph.14749 License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Ion channels. British Journal of Pharmacology (2019) 176, S142–S228 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels Stephen PH Alexander1 , Alistair Mathie2 ,JohnAPeters3 , Emma L Veale2 , Jörg Striessnig4 , Eamonn Kelly5, Jane F Armstrong6 , Elena Faccenda6 ,SimonDHarding6 ,AdamJPawson6 , Joanna L Sharman6 , Christopher Southan6 , Jamie A Davies6 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 3Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 4Pharmacology and Toxicology, Institute of Pharmacy, University of Innsbruck, A-6020 Innsbruck, Austria 5School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 6Centre for Discovery Brain Science, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties.
[Show full text]
Genomics of Inherited Bone Marrow Failure and Myelodysplasia Michael
Genomics of inherited bone marrow failure and myelodysplasia Michael Yu Zhang A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Washington 2015 Reading Committee: Mary-Claire King, Chair Akiko Shimamura Marshall Horwitz Program Authorized to Offer Degree: Molecular and Cellular Biology 1 ©Copyright 2015 Michael Yu Zhang 2 University of Washington ABSTRACT Genomics of inherited bone marrow failure and myelodysplasia Michael Yu Zhang Chair of the Supervisory Committee: Professor Mary-Claire King Department of Medicine (Medical Genetics) and Genome Sciences Bone marrow failure and myelodysplastic syndromes (BMF/MDS) are disorders of impaired blood cell production with increased leukemia risk. BMF/MDS may be acquired or inherited, a distinction critical for treatment selection. Currently, diagnosis of these inherited syndromes is based on clinical history, family history, and laboratory studies, which directs the ordering of genetic tests on a gene-by-gene basis. However, despite extensive clinical workup and serial genetic testing, many cases remain unexplained. We sought to define the genetic etiology and pathophysiology of unclassified bone marrow failure and myelodysplastic syndromes. First, to determine the extent to which patients remained undiagnosed due to atypical or cryptic presentations of known inherited BMF/MDS, we developed a massively-parallel, next- generation DNA sequencing assay to simultaneously screen for mutations in 85 BMF/MDS genes. Querying 71 pediatric and adult patients with unclassified BMF/MDS using this assay revealed 8 (11%) patients with constitutional, pathogenic mutations in GATA2 , RUNX1 , DKC1 , or LIG4 . All eight patients lacked classic features or laboratory findings for their syndromes.
[Show full text]
Downloaded Per Proteome Cohort Via the Web- Site Links of Table 1, Also Providing Information on the Deposited Spectral Datasets
www.nature.com/scientificreports OPEN Assessment of a complete and classifed platelet proteome from genome‑wide transcripts of human platelets and megakaryocytes covering platelet functions Jingnan Huang1,2*, Frauke Swieringa1,2,9, Fiorella A. Solari2,9, Isabella Provenzale1, Luigi Grassi3, Ilaria De Simone1, Constance C. F. M. J. Baaten1,4, Rachel Cavill5, Albert Sickmann2,6,7,9, Mattia Frontini3,8,9 & Johan W. M. Heemskerk1,9* Novel platelet and megakaryocyte transcriptome analysis allows prediction of the full or theoretical proteome of a representative human platelet. Here, we integrated the established platelet proteomes from six cohorts of healthy subjects, encompassing 5.2 k proteins, with two novel genome‑wide transcriptomes (57.8 k mRNAs). For 14.8 k protein‑coding transcripts, we assigned the proteins to 21 UniProt‑based classes, based on their preferential intracellular localization and presumed function. This classifed transcriptome‑proteome profle of platelets revealed: (i) Absence of 37.2 k genome‑ wide transcripts. (ii) High quantitative similarity of platelet and megakaryocyte transcriptomes (R = 0.75) for 14.8 k protein‑coding genes, but not for 3.8 k RNA genes or 1.9 k pseudogenes (R = 0.43–0.54), suggesting redistribution of mRNAs upon platelet shedding from megakaryocytes. (iii) Copy numbers of 3.5 k proteins that were restricted in size by the corresponding transcript levels (iv) Near complete coverage of identifed proteins in the relevant transcriptome (log2fpkm > 0.20) except for plasma‑derived secretory proteins, pointing to adhesion and uptake of such proteins. (v) Underrepresentation in the identifed proteome of nuclear‑related, membrane and signaling proteins, as well proteins with low‑level transcripts.
[Show full text]
And Cystein Cathepsin-Dependent Cancer Cells Invasiveness
Oncogene (2011) 30, 2108–2122 & 2011 Macmillan Publishers Limited All rights reserved 0950-9232/11 www.nature.com/onc ORIGINAL ARTICLE P2X7 receptor activation enhances SK3 channels- and cystein cathepsin-dependent cancer cells invasiveness B Jelassi1, A Chantoˆme1, F Alcaraz-Pe´rez2, A Baroja-Mazo3, ML Cayuela2, P Pelegrin3,4, A Surprenant4 and S Roger1 1Inserm U921, Universite´ Franc¸ois Rabelais de Tours, 10 Boulevard Tonnelle´, Tours, France; 2Telomerase, Cancer and Aging Group, University Hospital ‘Virgen de la Arrixaca’-FFIS, Carretera Palmar, Murcia, Spain; 3Inﬂammation and Experimental Surgery Group, University Hospital ‘Virgen de la Arrixaca’-FFIS, Carretera Palmar, Murcia, Spain and 4Faculty of Life Science, Michael Smith Building D3315, University of Manchester, Manchester, UK ATP-gated P2X7 receptors (P2X7R) are unusual plasma cancer patients do not die because of local complications membrane ion channels that have been extensively studied of their primary solid tumour growth, which are in immune cells. More recently, P2X7R have been relatively well treated, but rather to the appearance of described as potential cancer cell biomarkers. However, metastases. The development of metastases consists of a mechanistic links between P2X7R and cancer cell complex series of events accomplished by tumour cells processes are unknown. Here, we show, in the highly after they acquire numerous abilities, one of which being aggressive human breast cancer cell line MDA-MB-435s, the acquisition of an invasive potency. This mainly lies that P2X7 receptor is highly expressed and fully into an enhanced migration and the ability to digest the functional. Its activation is responsible for the extension extracellular matrix (Gupta and Massague, 2006).
[Show full text]
Pro-Inflammatory Role of P2Y6 Receptor Signalling During Vascular Inflammation
Aus der Universitätsklinik für Anästhesiologie und Intensivmedizin Tuebingen Ärztlicher Direktor: Professor Dr. P. Rosenberger Pro-inflammatory role of P2Y6 receptor signalling during vascular inflammation Inaugural Dissertation zur Erlangung des Doktorgrades der Medizin der Medizinischen Fakultät der Eberhard Karls Universität zu Tübingen vorgelegt von Ann-Kathrin Riegel, geb. Stenz, aus Herrenberg 2011 Dekan: Professor Dr. I. B. Autenrieth 1. Berichterstatter: Professor Dr. H.K. Eltzschig 2. Berichterstatter: Professor Dr. Dr. K. Zacharowski 3. Berichterstatterin: Professor Dr. C.E. Mueller To my parents Helga and Dr. Rainer Stenz, to my sisters Carolin Franziska and Kerstin Julia Stenz to Jens-Jochen Riegel and Margit, Adam, Max, Christel, Dagmar and Martin, to my grandparents and to my family-in-law :-) Abbreviations 1321 N1 astrocytoma Human glial cell line from brain astrocytoma, naturally cell line lacking any known P2 receptor A1 Adenosine receptor type 1 A2a Adenosine receptor type 2a A2b Adenosine receptor type 2b A3 Adenosine receptor type 3 AC Adenylate cyclase ADP Adenosine Diphosphate AMP Adenosine Monophosphate ATP Adenosine Triphosphate BSA Bovine Serum Albumine Ca2+ Calcium cAMP Cyclic Adenosine Monophosphate CD39 Ecto-Apyrase CD73 Ecto-5’-nucleotidase CDP Cytidine diphosphate COX-2 Cyclooxygenase 2 CTP Cytidine triphosphate DNA Deoxyribonucleic Acid DMSO Dimethyl sulfoxide ERK 1/2 Extracellular signal-regulated kinases 1 and 2 = specific subset of MAPK GDP Guanosine diphosphate G-protein Guanine-nucleotide binding protein Gαq α-subunit of heterotrimeric Gq-proteins Gi Heterotrimeric G-protein that inhibits the production of cAMP from ATP. Gq/11 Family of heterotrimeric G-proteins that stimulate the membrane-bound PLC-ß and increase the intracellular concentration of IP3 and cAMP.
[Show full text]
Cells Δγ Lineage Choice and Shapes Peripheral Purinergic P2X7
Purinergic P2X7 Receptor Drives T Cell Lineage Choice and Shapes Peripheral δγ Cells This information is current as Michela Frascoli, Jessica Marcandalli, Ursula Schenk and of September 29, 2021. Fabio Grassi J Immunol 2012; 189:174-180; Prepublished online 30 May 2012; doi: 10.4049/jimmunol.1101582 http://www.jimmunol.org/content/189/1/174 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2012/05/30/jimmunol.110158 Material 2.DC1 http://www.jimmunol.org/ References This article cites 31 articles, 15 of which you can access for free at: http://www.jimmunol.org/content/189/1/174.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 29, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Purinergic P2X7 Receptor Drives T Cell Lineage Choice and Shapes Peripheral gd Cells Michela Frascoli,* Jessica Marcandalli,* Ursula Schenk,*,1 and Fabio Grassi*,† TCR signal strength instructs ab versus gd lineage decision in immature T cells.
[Show full text]
Autocrine IFN Signaling Inducing Profibrotic Fibroblast Responses By
Downloaded from http://www.jimmunol.org/ by guest on September 23, 2021 Inducing is online at: average * The Journal of Immunology , 11 of which you can access for free at: 2013; 191:2956-2966; Prepublished online 16 from submission to initial decision 4 weeks from acceptance to publication August 2013; doi: 10.4049/jimmunol.1300376 http://www.jimmunol.org/content/191/6/2956 A Synthetic TLR3 Ligand Mitigates Profibrotic Fibroblast Responses by Autocrine IFN Signaling Feng Fang, Kohtaro Ooka, Xiaoyong Sun, Ruchi Shah, Swati Bhattacharyya, Jun Wei and John Varga J Immunol cites 49 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2013/08/20/jimmunol.130037 6.DC1 This article http://www.jimmunol.org/content/191/6/2956.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 23, 2021. The Journal of Immunology A Synthetic TLR3 Ligand Mitigates Proﬁbrotic Fibroblast Responses by Inducing Autocrine IFN Signaling Feng Fang,* Kohtaro Ooka,* Xiaoyong Sun,† Ruchi Shah,* Swati Bhattacharyya,* Jun Wei,* and John Varga* Activation of TLR3 by exogenous microbial ligands or endogenous injury-associated ligands leads to production of type I IFN.
[Show full text]
Supplemental Figures 04 12 2017
Jung et al. 1 SUPPLEMENTAL FIGURES 2 3 Supplemental Figure 1. Clinical relevance of natural product methyltransferases (NPMTs) in brain disorders. (A) 4 Table summarizing characteristics of 11 NPMTs using data derived from the TCGA GBM and Rembrandt datasets for 5 relative expression levels and survival. In addition, published studies of the 11 NPMTs are summarized. (B) The 1 Jung et al. 6 expression levels of 10 NPMTs in glioblastoma versus non‐tumor brain are displayed in a heatmap, ranked by 7 significance and expression levels. *, p<0.05; **, p<0.01; ***, p<0.001. 8 2 Jung et al. 9 10 Supplemental Figure 2. Anatomical distribution of methyltransferase and metabolic signatures within 11 glioblastomas. The Ivy GAP dataset was downloaded and interrogated by histological structure for NNMT, NAMPT, 12 DNMT mRNA expression and selected gene expression signatures. The results are displayed on a heatmap. The 13 sample size of each histological region as indicated on the figure. 14 3 Jung et al. 15 16 Supplemental Figure 3. Altered expression of nicotinamide and nicotinate metabolism‐related enzymes in 17 glioblastoma. (A) Heatmap (fold change of expression) of whole 25 enzymes in the KEGG nicotinate and 18 nicotinamide metabolism gene set were analyzed in indicated glioblastoma expression datasets with Oncomine. 4 Jung et al. 19 Color bar intensity indicates percentile of fold change in glioblastoma relative to normal brain. (B) Nicotinamide and 20 nicotinate and methionine salvage pathways are displayed with the relative expression levels in glioblastoma 21 specimens in the TCGA GBM dataset indicated. 22 5 Jung et al. 23 24 Supplementary Figure 4.
[Show full text]
Supplementary Information
Electronic Supplementary Material (ESI) for Molecular BioSystems. This journal is © The Royal Society of Chemistry 2014 Supplementary Information High-throughput synthesis of stable isotope-labeled transmembrane proteins for targeted transmembrane proteomics using a wheat germ cell-free protein synthesis system Nobuaki Takemori a*, Ayako Takemori a, Kazuhiro Matsuoka ab, Ryo Morishita c, Natsuki Matsushita d, Masato Aoshima e, Hiroyuki Takeda ab, Tatsuya Sawasaki ab, Yaeta Endo b, and Shigeki Higashiyama a a Proteo-Science Center, Ehime University, Ehime, Japan b Cell-Free Science and Technology Research Center, Ehime University, Ehime, Japan, c CellFree Sciences Co., Ltd., Ehime, Japan, d Translational Research Center, Ehime University Hospital, Ehime, Japan, e K.K. AB SCIEX, Tokyo, Japan * Corresponding author E-mail: [email protected] Contents • Experimental Procedure • Supplementary Results • Supplementary Figures (5 figures) Fig. S1: Highly effective incorporation of stable isotope (SI)-labeled amino acids in a bilayer cell-free system. Fig. S2: A workflow diagram for the bilayer cell-free synthesis of transmembrane proteins. Fig. S3: SDS-PAGE images of mouse transmembrane proteins. Fig. S4: Western blot analysis of mouse GRIA3 in six brain regions. Fig. S5: Expression profiles of endogenous neurotransmitter receptors in six brain regions. • Supplementary Tables (7 tables; see “Supplementary Table.xlsx”) 1. Experimental Procedure 1.1 Concurrent synthesis of SI-labeled TMPs using WG-CFS We selected 263 cDNA clones encoding TMPs of interest from the Functional Annotation of Mouse (FANTOM) full-length cDNA library (DNAFORM, Yokohama, Japan). Split-primer PCR was performed using specific primers to produce DNA templates for in vitro transcription, as described previously.24 A peptide tag sequence (MGPGGRAIIIRAAQAGTVR) was designed to measure the absolute amount of synthesized TMPs using the tryptic fragment AIIIR; the specific nucleotide sequence of the tag peptide was fused to each targeted TMP cDNA at the 5ʹ end.
[Show full text]